Sienna Cancer Diagnostics (ASX:SDX), a commercial stage, medical technology company focussed on the development and commercialisation of cancer-related tests, has listed on the ASX today after raising $4.6 million from the Initial Public Offering (IPO).
The IPO was conducted by lead manager, Sequoia Corporate Finance.
Sienna’s IVD product detects hTERT, a component of telomerase, a biomarker found in nearly all epithelial cancers. The company says its test allows pathology labs to detect this biomarker as an adjunct to urine cytology, to assist in the diagnosis of bladder cancer.
Matthew Hoskin, CEO of Sienna Diagnostics said, “This is an exciting time for investors to be joining Sienna, with commercial sales already underway, the Company is now poised for product revenue growth. The funds raised through the IPO will support this marketing and scale up to support a broader geographic base, while also providing the opportunity to develop further clinical applications.”